ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

AMRN Amarin Corp

92.50
0.00 (0.00%)
19 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Amarin Corp LSE:AMRN London Ordinary Share GB00B29VL935 ORD 50P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 92.50 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Notice of AGM

19/06/2007 1:56pm

UK Regulatory


RNS Number:6263Y
Amarin Corporation Plc
19 June 2007



                             AMARIN CORPORATION PLC

LONDON, United Kingdom, June 19, 2007, Amarin Corporation plc ("Amarin" or
"Company") announces that it is sending to its shareholders today the following
documentation in relation to its Annual General Meeting to be held at 7 Curzon
Street, Mayfair, London W1J 5HG on July 19, 2007, a Notice of the Annual General
Meeting, a Proxy Form, a copy of its Annual Report for the year ended December
31, 2006 and a letter regarding the potential future communication of
shareholder information by electronic means. A copy of each of these documents
is available on the Company's website at 

http://www.amarincorp.com/investor_relations/investor_relations.424.html

About Amarin

Amarin is committed to improving the lives of patients suffering from diseases
of the central nervous system.  Our goal is to be a leader in the research,
development and commercialization of novel drugs that address unmet patient
needs.

Amarin's core development pipeline includes, in addition to Miraxion for several
therapeutic indications, four other key development programs in Parkinson's
disease, epilepsy seizures, memory and cognition and our proprietary
pre-clinical combinatorial lipid program.

Amarin has its primary stock market listing in the U.S. on NASDAQ ("AMRN") and
secondary listings in the U.K. and Ireland on AIM ("AMRN") and IEX ("H2E"),
respectively.

For press releases and other corporate information, visit the Amarin website at
http://www.amarincorp.com. Information on our website does not form part of this
press release.

Contacts:

Amarin

+44 (0) 207 907 2442

Rick Stewart, Chief Executive Officer

Alan Cooke, President and Chief Financial Officer

investor.relations@amarincorp.com


Investors:

Lippert/Heilshorn & Associates, Inc.

Anne Marie Fields , +1 212 838 3777

Bruce Voss, +1 310 691 7100

Media:

Powerscourt

+44 (0) 207 250 1446

Rory Godson

Ends.


                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
NOAUKSURBKRNAAR

1 Year Amarin Chart

1 Year Amarin Chart

1 Month Amarin Chart

1 Month Amarin Chart

Your Recent History

Delayed Upgrade Clock